Evidence map›Paper›PMID 37383237›Full record

ArticleFrontiers in immunology2023

Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas - comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients.

Moritz Knebel, Sandrina Körner, Jan Philipp Kühn, Silke Wemmert, Lukas Brust, Sigrun Smola, Mathias Wagner, Rainer M Bohle, Luc G T Morris, Abhinav Pandey and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Type I conventional dendritic cells and CD8Frontiers in immunology · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Moritz KnebelDepartment of Otorhinolaryngology, Saarland University Medical Center, Homburg, Saar, Germany.
Sandrina KörnerDepartment of Otorhinolaryngology, Saarland University Medical Center, Homburg, Saar, Germany.
Jan Philipp KühnDepartment of Otorhinolaryngology, Saarland University Medical Center, Homburg, Saar, Germany.
Silke WemmertDepartment of Otorhinolaryngology, Saarland University Medical Center, Homburg, Saar, Germany.
Lukas BrustDepartment of Otorhinolaryngology, Saarland University Medical Center, Homburg, Saar, Germany.
Sigrun SmolaInstitute of Virology, Saarland University Medical Center, Homburg, Saar, Germany.
Mathias WagnerDepartment of General and Surgical Pathology, Saarland University Medical Center, Homburg, Saar, Germany.
Rainer M BohleDepartment of General and Surgical Pathology, Saarland University Medical Center, Homburg, Saar, Germany.
Luc G T MorrisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY, United States.
Abhinav PandeyWeill Cornell School of Medical Sciences, New York City, NY, United States.
Bernhard SchickDepartment of Otorhinolaryngology, Saarland University Medical Center, Homburg, Saar, Germany.
Maximilian LinxweilerDepartment of Otorhinolaryngology, Saarland University Medical Center, Homburg, Saar, Germany.
Saarland University · DECornell University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Due to the expanding role of immune checkpoint inhibition in the treatment of head and neck squamous cell carcinoma, understanding immunological processes in the tumor microevironment (TME) has strong translational importance. Though analytical methods for a comprehensive analysis of the immunological TME have constantly improved and expanded over the past years the prognostic relevance of immune cell composition in head and neck cancer TME largely remains ambiguous with most studies focusing on one or a small subset of immune cells. Methods: The overall survival (OS) of the TCGA-HNSC patient cohort comprising 513 head and neck cancer patients was correlated with a total of 29 different immune metrics including a wide spectrum of immune cell subpopulations as well as immune checkpoint receptors and cytokines using RNAseq based immune deconvolution analyses. The most significant predictors of survival among these 29 immune metrics were validated on a separate HNSCC patient cohort (n=101) using immunohistochemistry: CD3, CD20+CXCR5, CD4+CXCR5, Foxp3 and CD68. Results: Overall immune infiltration irrespective of immune cell composition showed no significant correlation with the patients' overall survival in the TCGA-HNSC cohort. However, when focusing on different immune cell subpopulations, naïve B cells (p=0.0006), follicular T-helper cells (p<0.0001), macrophages (p=0.0042), regulatory T cells (p=0.0306), lymphocytes (p=0.0001), and cytotoxic T cells (p=0.0242) were identified as highly significant predictors of improved patient survival. Using immunohistochemical detection of these immune cells in a second independent validation cohort of 101 HNSCC patients, we confirmed the prognostic relevance of follicular T helper cells, cytotoxic T cells and lymphocytes. In multivariable analysis, HPV negativity and advanced UICC stages were identified as additional prognostic biomarkers associated with poor outcome. Conclusion: Our study highlights the prognostic relevance of the immunological tumor environment in head and neck cancer and demonstrates that a more detailed analysis of immune cell composition and immune cell subtypes is necessary to accurately prognosticate. We observed the highest prognostic relevance for lymphocytes, cytotoxic T cells, and follicular T helper cells, suggesting further investigations focusing on these specific immune cell subpopulations not only as predictors of patient prognosis but also as promising targets of new immunotherapeutic strategies.

Indexed as

Head and Neck NeoplasmsT-Lymphocytes, Helper-InducerB-LymphocytesHumansPrognosisSquamous Cell Carcinoma of Head and NeckHNSCC (head and neck squamous cell carcinoma)immunological tumor microenvironmentimmunotherapyprognostic biomarkersThe Cancer Genome Atlas

Identifiers

PMID37383237
PMCPMC10294051
OpenAlexW4380629895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.